GB Sciences Is Maximizing the Production of Critical Medical Components from Specific Cannabis Strains

LAS VEGAS, Dec. 8, 2018 /CNW/ -- GB Sciences, Inc. (OTCQB: GBLX) currently markets both medical and adult use cannabis products in Nevada under the respected Cultivation Labs brand. The Company has selected and nurtured several cannabis strains that are scoring some of the highest testing lab results seen in the Nevada market, according to the chemoprofile test results from DigiPath Labs.

But this is only one half of the story. By maximizing the production of critical raw materials that can only be derived from the cannabis plant, GB Sciences is able to provide the base materials for their proprietary cannabis-based medical formulations. This breakthrough places cannabis-based medical formulations on a level playing field with traditional medical formulations when it comes to patient studies and clinical trials; a task that, until now, has proven extremely difficult industry-wide.

John Poss, Chairman and CEO stated, "Cannabis-based formulations can now move past anecdotal evidence and instead provide hard, verifiable data to prove safety and efficacy. This changes everything. This is the basis of real medicine."

The latest proven strain in GB Sciences' ongoing research is WiFi OG, a 60% sativa dominant hybrid. The tissue propagation unit regenerated the strain using the GB Sciences' proprietary tissue culture process to get a proper volume of test plants to facilitate research. This process not only ensures zero mold or bacteria in the mother plants, but also allows GB Sciences to create libraries of healthy strains.

The Cultivation Labs unit then placed the strain into their precision controlled growing environments and optimized the strain-specific growing conditions, enhancing the yield of critical components useful in both the recreational market and as the ingredients in the proprietary medical formulations.

"GB Sciences has clearly established that plant husbandry is a key variable that can be exploited to maximize the inherent genetic potential in a given cannabis strain for an enhanced phenotypic outcome as observed in chemoprofiles," shared Digipath's Chief Science Officer Cindy Orser, Ph.D.

"It's no surprise that the test results get better over time as we dial-in the environmental conditions to meet the specific needs of each strain", said Kevin Kuethe, COO of GB Sciences.  "We are now able to modify the environmental controls to allow each specific strain to maximize the production of these key cannabinoids and terpenes."

Mr. Poss concluded, "GB Sciences was founded on the belief that all people who consume cannabis, regardless of the labels of medical or adult use, are patients of one sort or another. And we could find no one in the industry who had taken the time or made the effort to solve the most basic issue involved in making real medicine... creating pure, trusted, and abundant base ingredients for their medical formulations. Without that element, all the evidence is purely anecdotal. So, this is where we focused our efforts. Research is in our corporate DNA, and it's beginning to pay off."

About GB Sciences, Inc.
GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company's goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.

Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements.  Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control.  It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements.  Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov.  All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Note:  Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.

Contact Information
GB Sciences, Inc., 3550 West Teco Ave., Las Vegas, NV 89118
866-721-0297, or 
Tom Arcuragi, SR VP Marketing, tom@gbsciences.com, http://gbsciences.com

View original content with multimedia:http://www.prnewswire.com/news-releases/gb-sciences-is-maximizing-the-production-of-critical-medical-components-from-specific-cannabis-strains-300578642.html

SOURCE GB Sciences, Inc.